Given the exquisite sensitivity of SMARCB1-deficient cells to BRD9 inhibition [30,31], we hypothesized that BRD9/BRG1 peaks would occupy activate promoters associated with the hallmarks of cancer. The gene discussed is SMARCB1; the disease is cancer.